Tango Therapeutics, Inc. (TNGX)
| Market Cap | 3.10B +1,943.6% |
| Revenue (ttm) | 56.99M +39.0% |
| Net Income | -107.23M |
| EPS | -0.86 |
| Shares Out | 144.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 998,356 |
| Open | 20.06 |
| Previous Close | 20.00 |
| Day's Range | 19.75 - 21.45 |
| 52-Week Range | 1.93 - 28.41 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | 31.90 (+48.79%) |
| Earnings Date | May 13, 2026 |
About TNGX
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to ... [Read more]
Financial Performance
In 2025, Tango Therapeutics's revenue was $62.38 million, an increase of 48.29% compared to the previous year's $42.07 million. Losses were -$101.59 million, -22.03% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for TNGX stock is "Buy." The 12-month stock price target is $31.9, which is an increase of 48.79% from the latest price.
News
Tango Therapeutics falls -19.7%
Tango Therapeutics (TNGX) is down -19.7%, or -$4.89 to $19.98.
Tango Therapeutics falls -14.9%
Tango Therapeutics (TNGX) is down -14.9%, or -$3.71 to $21.16.
Tango Therapeutics price target raised to $30 from $20 at Mizuho
Mizuho analyst Joseph Catanzaro raised the firm’s price target on Tango Therapeutics (TNGX) to $30 from $20 and keeps an Outperform rating on the shares post the Q1 report. The…
Tango Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler downgraded Tango Therapeutics (TNGX) to Neutral from Overweight with a price target of $24, up from $16.
Piper Sandler cuts Tango Therapeutics Neutral following Q1 report
As previously reported, Piper Sandler downgraded Tango Therapeutics (TNGX) to Neutral from Overweight with a price target of $24, up from $16. The firm noted that when Tango reported its…
Tango Therapeutics price target raised to $55 from $28 at Leerink
Leerink raised the firm’s price target on Tango Therapeutics (TNGX) to $55 from $28 and keeps an Outperform rating on the shares after the company reported Q1 results and updated…
Tango Therapeutics price target raised to $33 from $19 at Wedbush
Wedbush raised the firm’s price target on Tango Therapeutics (TNGX) to $33 from $19 to incorporate recent financing activities and evolving vopimetostat development, while keeping an Outperform rating...
Tango Therapeutics downgraded to Hold from Buy at Jefferies
Jefferies analyst Maury Raycroft downgraded Tango Therapeutics (TNGX) to Hold from Buy with a price target of $27, up from $18. The company remains on-track to show PRMT5+RAS combo pancreatic…
Tango Therapeutics reports Q1 EPS (32c), consensus (31c)
Reports Q1 revenue $0 vs. $5.4M last year “We continue to work diligently to advance vopimetostat towards pivotal development in pancreatic cancer and remain highly encouraged by the potential of…
Tango Therapeutics sees cash runway into 2028
As of March 31, 2026, the Company held $379.8 million in cash, cash equivalents and marketable securities, which the Company expects to fund operations into 2028.
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
First clinical data from PRMT5/RAS(ON) combination trial to be pre sented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection point...
Tango Therapeutics Quarterly report: Q1 2026
Tango Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Tango Therapeutics Earnings release: Q1 2026
Tango Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors grant...
Tango Therapeutics price target raised to $40 from $24 at Stifel
Stifel raised the firm’s price target on Tango Therapeutics (TNGX) to $40 from $24 and keeps a Buy rating on the shares, citing increased conviction for the PRMT5 inhibitor +…
Tango Therapeutics Proxy statement: Proxy filing
Tango Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Tango Therapeutics Proxy statement: Proxy filing
Tango Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
- Matthew Gall appointed Chief Financial Officer - - Additional key appointments add expertise in clinical operations, corporate strategy and project leadership -
Canaccord starts Tango Therapeutics with Buy on PRMT5 inhibitor
Canaccord initiated coverage of Tango Therapeutics (TNGX) with a Buy rating and $30 price target Tango is a precision oncology company with a “best-in-class” PRMT5 inhibitor for MTAP-deleted cancer, t...
Tango Therapeutics initiated with a Buy at Canaccord
Canaccord initiated coverage of Tango Therapeutics (TNGX) with a Buy rating and $30 price target
Tango Therapeutics price target raised to $21 from $14 at B. Riley
B. Riley raised the firm’s price target on Tango Therapeutics (TNGX) to $21 from $14 and keeps a Buy rating on the shares. Shares have rebounded sharply despite limited new…
Tango Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The session highlighted progress in PRMT5 inhibitor development, with vopimetostat showing promising efficacy and safety in pancreatic cancer and ongoing combination trials with RAS inhibitors. New collaborations and a brain-penetrant compound expand the pipeline, aiming to transform treatment options.
Tango Therapeutics price target raised to $20 from $19 at Mizuho
Mizuho raised the firm’s price target on Tango Therapeutics (TNGX) to $20 from $19 and keeps an Outperform rating on the shares. The firm updated the company’s model post the…
Tango Therapeutics price target raised to $24 from $15 at Stifel
Stifel analyst Laura Prendergast raised the firm’s price target on Tango Therapeutics (TNGX) to $24 from $15 and keeps a Buy rating on the shares. The firm views the “recent…
Tango Therapeutics price target raised to $19 from $15 at Wedbush
Wedbush raised the firm’s price target on Tango Therapeutics (TNGX) to $19 from $15 and keeps an Outperform rating on the shares after the company reported fourth quarter financials and…